(Q53040289)

10 May 2018

editorial

0 references

title

Immunoscoring breast cancer: TILs remember what they target. (English)

1 reference

10 May 2018

author

Giuseppe Curigliano

series ordinal

1

1 reference

10 May 2018

author name string

E A Perez

series ordinal

2

1 reference

10 May 2018

publication date

20 June 2014

1 reference

10 May 2018

published in

Annals of Oncology

1 reference

10 May 2018

volume

25

1 reference

10 May 2018

issue

8

1 reference

10 May 2018

page(s)

1455-1456

1 reference

10 May 2018

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU227

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU227

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU227

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU227

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU227

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU227

Immune parameters affecting the efficacy of chemotherapeutic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU227

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU227

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU227

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU227

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU227

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU227

1 reference

10 May 2018

1 reference

10 May 2018